Association of Decompensated Cirrhosis with Acute Clinical and Financial Outcomes Following Cardiac Operations

Konmal Ali

doi:10.1016/j.surg.2026.110394

Subgroup Analysis of Pooled Phase 3 Efficacy Data from Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) including Participants with Uropathogens Not-Susceptible to Nitrofurantoin

2026-07-08

0

OA

AI

A

Amanda Sheets, PhD *

J

Jeremy Dennison, MBChB

J

Jennifer H Han, MD

S

Sarah Watts, MSc

C

Caroline Perry, PhD

N

Nicole E Scangarella-Oman, MSc

D

Deborah Butler, BS

J

John Breton, MCM

T

Thomas M Hooton, MD

H

Helen Millns, PhD

M

Matthew Helgeson, PharmD

S

Salim Janmohamed, MBBS

DOI：10.1093/cid/ciag408

Original

Original request for help

Save

Abstract

En 中文

Two Phase 3 trials (EAGLE-2 [NCT04020341]/EAGLE-3 [NCT04187144]) demonstrated the efficacy of gepotidacin, a novel, first-in-class triazaacenaphthylene antibacterial, versus nitrofurantoin for the treatment of uncomplicated urinary tract infections (uUTIs). Using pooled data, we assessed gepotidacin efficacy across clinically important subgroups, including participants with nitrofurantoin not-susceptible (NTF-NS; i.e., resistant, intermediate or no interpretation) uropathogens.

Subgroup Analysis of Pooled Phase 3 Efficacy Data from Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) including Participants with Uropathogens Not-Susceptible to Nitrofurantoin

Abstract

Journal

Organization

Cited Papers

Citing Papers